SCHEMBL5029172

SCHEMBL5029172

Cc1ccc(Nc2nc(Cl)nc(NC3CCCCCC3)n2)cc1F

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.70
PDE4A P27815 1/20 0.52
APP P05067 1/20 0.49
PTGS2 P35354 1/20 0.48
CTSS P25774 3/20 0.47
CTSK P43235 3/20 0.47
CTSV O60911 2/20 0.47
PLAT P00750 2/20 0.47
CTSL P07711 2/20 0.47
CTSH P09668 2/20 0.47
CASP14 P31944 2/20 0.47
CASP6 P55212 2/20 0.47
CTSZ Q9UBR2 2/20 0.47
BCL6 P41182 1/20 0.47
CTSB P07858 1/20 0.46
CASP4 P49662 1/20 0.46
CASP5 P51878 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14294391 0.86 RAB9A (0.62) RAB9APDE4APTGS2CTSSCTSK
SCHEMBL4838260 0.85 RAB9A (0.62) RAB9APDE4AAPPPTGS2CTSS
SCHEMBL14268519 0.84 RAB9A (0.49) RAB9ACTSSCTSKCTSVPLAT
SCHEMBL5033983 0.82 APP (0.60) RAB9AAPP
SCHEMBL14293830 0.81 RAB9A (0.67) RAB9APDE4APTGS2CTSSCTSK
SCHEMBL5031260 0.81 RAB9A (0.62) RAB9APDE4ACTSSCTSKCTSV
SCHEMBL3503380 0.79 RAB9A (0.80) RAB9APDE4APTGS2CTSSCTSK
SCHEMBL14293983 0.79 RAB9A (0.53) RAB9AAPPPTGS2CTSSCTSK
SCHEMBL4832399 0.79 RAB9A (0.53) RAB9AAPPBCL6
SCHEMBL13326019 0.79 RAB9A (0.66) RAB9APDE4APTGS2CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7335770-B2 Triazine compounds and their analogs, compositions, and methods REDDY U5 THERAPEUTICS, INC. (US) 2008-02-26 US disclosed
US-7335770-B2 Triazine compounds and their analogs, compositions, and methods REDDY U5 THERAPEUTICS, INC. (US) 2008-02-26 US disclosed
US-7335770-B2 Triazine compounds and their analogs, compositions, and methods REDDY U5 THERAPEUTICS, INC. (US) 2008-02-26 US disclosed
US-20050227983-A1 Triazine compounds and their analogs, compositions, and methods DR. REDDY'S LABORATORIES LTD. (IN) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227983-A1 Triazine compounds and their analogs, compositions, and methods MYLK, SMAD3, GID4 RAB9A 3708/4885PDE4A 1438/4885APP 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.